Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Stomach Neoplasms 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Neoplasms 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Gastrointestinal Stromal Tumors 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1

Interventions

Doxorubicin 6Ifosfamide 5Radiotherapy 4pazopanib 3cediranib 3atezolizumab 3Sunitinib 3selinexor 2perifosine 2pembrolizumab 2Trabectedin 2Specimen Handling 2Loperamide 2Gemcitabine 2Filgrastim 2Dacarbazine 2Cisplatin 2Biopsy 2Bevacizumab 2trifluridine tipiracil drug combination 1spartalizumab 1sargramostim 1romidepsin 1lentiviral minigene vaccine of COVID-19 coronavirus 1ixazomib 1indolepropanol phosphate 1futibatinib 1fludarabine 1cabozantinib 1brostallicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Alveolar Soft Part × TAS-116 × Clear all
NCT04999761 2024-09-25

AB122 Platform Study

Taiho Pharmaceutical Co., Ltd.

Phase 1 Recruiting
917 enrolled
GastrointestinalHead & NeckSarcomaThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Sarcoma, Alveolar Soft Part

Data powered by HemOnc (CC BY 4.0) Colophon âš¡